Table 1.
MELD 11-20 group (n=9) | MELD 21-28 group (n=9) | |
---|---|---|
Age (years) | 51.5 ± 9.7 | 46.8 ± 9.9 |
Female (%) | 22.2% (2/9) | 44.4% (4/9) |
Race | 100% White (9/9) | 89.9% white (8/9), 11.1% American Indian (1/9) |
Alcohol consumption (g/day) | 175 ± 91.5 | 145.5 ± 102.5 |
Hospitalized at screening (%) | 7/9 (77.8%) | 6/9 (66.7%) |
Days hospitalized prior to 1st dose | 4.2 ± 2.7 | 2.1 ± 2.0 |
Steroids use prior to first dose (%) | 11.1% (1/9) | 33.3% (3/9) |
Baseline infection | 0% (0/9) | 0% (0/9) |
WBC count (x109) | 9.4 ± 6.9 | 10.7 ± 5.6 |
Creatinine (mg/dL) | 0.81 ± 0.32 | 0.77 ± 0.19 |
AST (IU/L) | 151.5 ± 83.5 | 130.7 ± 67.0 |
ALT (IU/L) | 84.1 ± 38.0 | 66.5 ± 47.2 |
Bilirubin (mg/dL) | 6.8 ± 3.8 | 14.5 ± 8.6 |
Bilirubin at day 7 (mg/dL) | 4.2 ± 3.8 | 6.1 ± 2.5 |
Albumin (g/dL) | 2.8 ± 0.5 | 3.0 ± 0.7 |
INR | 1.4 ± 0.3 | 2.0 ± 0.3 |
C-reactive protein (g/dL) | 31.6 ± 27.2 | 12.4 ± 8.0 |
MELD | 17.3 ± 2.3 | 23.8 ± 2.7 |
Hepatic encephalopathy (%) | 2/9 (22.2%) | 1/9 (11.1%) |
Known cirrhosis (%) | 3/9 (33.3%) | 9/9 (100%) |
Liver biopsy (%) | 2/9 (22.2%) | 1/9 (11.1%) |
Data are presented as mean ± SD, or percentages.